Speaker Profile
M.D., Ph.D., Alex Grass Professor of Oncology, Co-Director, Thoracic Oncology & Cancer Genetics and Epigenetics Programs, Johns Hopkins Medicine
Biography
Dr. Anagnostou is a translational cancer investigator focused on large-scale genomic and liquid-biopsy analyses of human cancers. Her group has discovered novel genomic mechanisms underlying response and resistance to immunotherapy, and focuses on understanding how cancer cells acquire fitness advantages that enable them to evade immune elimination during immunotherapy. Her research aims to capturing residual disease and therapy resistance using minimally invasive assays and novel methods for circulating tumor DNA (ctDNA) detection, and on translating these approaches into innovative, molecularly guided treatment strategies for individuals with cancer. She is leading the design of ctDNA residual disease-adaptive immunotherapy clinical trials for patients with both early-stage and metastatic non-small cell lung cancer and holds leadership positions in national clinical trial cooperative groups. Her long-term goal is to transform medical oncology into personalized molecular oncology, in which treatment decisions are tailored to the evolving cancer genome and to real-time molecular response assessments informed by liquid biopsies.
Session Abstract – PMWC 2027 Silicon Valley
Track Chair:
Emre Baser, AstraZeneca
PMWC Award Ceremony
• Max Diehn, Stanford (Pioneer)
• Sarah-Jane Dawson, Peter MacCallum Cancer Centre / University of Melbourne (Luminary)
Featured Speakers
• Max Diehn, Stanford
• Sarah-Jane Dawson, University of Melbourne
• Phil Febbo, Veracyte
• Ash Alizadeh, Stanford
• Adrian Lee, University of Pittsburgh
• Emre Baser, AstraZeneca
• Keith Flaherty, Mass General
• Thomas Powles, Barts Cancer Institute
Early-Stage Cancer: Can MRD Decide Who Needs More Treatment?
When ctDNA should change escalation, de-escalation, and surveillance.
Advanced Cancer Monitoring
Detecting response, resistance, and relapse early enough to switch therapy.
From Blood to Drug
Liquid biopsy for therapy selection and matching patients to the right intervention.
Integrating Tissue, Liquid & Imaging Biomarkers
How multimodal monitoring should work in real oncology care.
MRD as a Surrogate Endpoint
The promise and hazards of using MRD to accelerate drug approval.
PMWC Hall of Impact
Previous Speakers Include
Nobel laureates, technology founders, regulators, CEOs and scientific pioneers who have taken the PMWC stage.
